ClinicalTrials.gg
CompletedNCT00658658Updated May 18, 2016Results posted

Panitumumab in Children With Solid Tumors

A Phase 1 interventional study of Panitumumab in Solid Tumors, sponsored by Amgen. Completed at 11 sites in United States. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-18.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
31
Allocation
Not applicable
Ages
1 Year to 17 Years
Sex
All
01

Study summary

The primary objective of this study was to evaluate the safety and pharmacokinetics of up to 3 different dose schedules of panitumumab in pediatric patients with solid tumors.

Read the detailed description

This is an open-label, multi-center, single arm, dose-ranging, clinical study. Panitumumab will be administered by intravenous infusion to 4-6 patients per cohort. Three planned cohorts, stratified by age, will be studied at 100% of the recommended panitumumab dose for each treatment schedule as defined in adults. Enrollment will start with a 2.5 mg/kg once weekly administration to the 12 to \< 18 year old patients. Upon demonstration of sufficient safety additional cohorts will open; a 2.5 mg/kg once weekly administration to the 1 to \< 12 year old patients and a 6.0 mg/kg once every two weeks to the 12 to \< 18 year old patients. The decision to advance to the next cohort will be based on observance of ≤ 33% incidence of a dose limiting toxicity during the evaluation period. Subsequent cohorts of 6.0 mg/kg once every two weeks to the 1 to \< 12 year old patients and 9.0 mg/kg once every three weeks to both age groups will open once sufficient safety in each cohort is determined. Participants may stay on study treatment until disease progression.

02

Conditions studied

  • Solid Tumors

Keywords

  • Epidermal Growth Factor
  • Pediatric
  • Solid Tumors
  • Panitumumab
  • Dose Limiting Toxicity
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Parents or legal guardian signed-written
  • 1 to \< 18 years of age
  • or cytologically confirmed solid tumor that has recurred after standard therapy, or for which there is no standard therapy. Subjects with brainstem glioma DO NOT need histologic proof of the diagnosis.
  • Paraffin-embedded tumor tissue from primary tumor or for determination of epidermal growth factor receptor expression and biomarker testing
  • Central nervous system tumors are allowed
  • Presence of measurable or non-.
  • of ≥ 12 weeks.
  • Performance status: ≥ 60% for 12 to \<18 years of age; Lansky play scale ≥ 60% for 1 to \< 12 years of age.
  • Adequate hematologic function.
  • Adequate renal function.
  • Adequate hepatic function.
  • Magnesium ≥ lower limit of normal (LLN)
  • Adequate pulmonary function
  • All previous therapy-related toxicities must have resolved or return to baseline.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease or other hematologic .
  • Any prior transplant.
  • Prior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to enrollment.
  • Substantial radiotherapy to the bone marrow within 6 weeks prior to enrollment.
  • Prior use of any monoclonal antibodies directly targeting the epidermal growth factor receptor (EGFr). Subjects who have received prior tyrosine kinase inhibitors such as gefitinib or erlotinib are eligible.
  • Immunotherapy, radiotherapy, or chemotherapy ≤ 2 weeks prior to enrollment. (≤ 6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and ≤ 6 weeks from prior antibody therapy).
  • Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except for pain control) or any other drug while on this study.
  • Prior seizures \< 3 months prior to enrollment. Subjects with a history of seizure disorders ≥ 3 months prior to enrollment must be seizure free and on stable anticonvulsant medication(s) for ≥ 3 months prior to enrollment).
  • Presence of a serious uncontrolled medical disorder.
  • Dementia, altered mental status, or any other medical condition or disorder that would prohibit the understanding or rendering of assent (if applicable), or ability to comply with study procedures.
  • Major surgery ≤ 28 days prior to enrollment.
  • Known or suspected history of interstitial lung disease.
  • Active inflammatory bowel disease or other bowel disease causing chronic diarrhea.
  • Known positive test for infection, virus, acute or chronic infection, or any co-morbid disease that would increase risk of toxicity.
  • Females of not using adequate precautions for the duration of the study treatment and for 2 months after the last administration of investigational product.
  • Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product.
  • Received investigational therapy or procedure ≤ 30 days prior to enrollment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Panitumumab

    Participants received panitumumab at planned doses ranging from 2.5 mg/kg weekly (QW) to 9.0 mg/kg every 3 weeks (Q3W) until the patient experienced disease progression, was unable to tolerate study drug, withdrew consent, or other reasons that warranted removal from the study.

    Biological: Panitumumab

Interventions

  • BiologicalPanitumumab

    Panitumumab administered by intravenous infusion

    Also known as: Vectibix

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicities (DLTs)

    Any panitumumab related grade 3 or 4 hematologic or non-hematologic toxicity (graded according to the modified Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria) was considered a DLT with the exception of alopecia and fatigue. Hypomagnesemia, nausea, diarrhea, vomiting, and skin or nail toxicities constituted a DLT only of the following occured: • Grade 3 or 4 hypomagnesemia that persisted for at least 5 days despite maximal magnesium replacement; • Grade 3 or 4 diarrhea, nausea, or vomiting that persisted for at least 5 days despite maximum supportive therapy; • Grade 4 skin or nail toxicity.

    Time frame: 28 days from initial administration of panitumumab for the 2.5 and 6 mg/kg cohorts and 21 days from first administration for the 9 mg/kg cohort.

  2. Number of Participants With Adverse Events (AEs)

    A serious adverse event is defined as an AE that: • is fatal; • is life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • is a congenital anomaly/birth defect; • other significant medical hazard. The investigator assessed whether adverse events were related to panitumumab. The severity of adverse events was based on CTCAE version 3 (with the exception of skin- or nail-related toxicities which were graded using the CTCAE version 3.0 with modifications), according to the following: Grade 1 = Mild (aware of sign or symptom, but easily tolerated); Grade 2 = Moderate (discomfort enough to cause interference with usual activity); Grade 3 = Severe (incapacitating with inability to work or do usual activity); Grade 4 = Life-threatening or disabling; Grade 5 = Fatal.

    Time frame: From first dose date to end of study date. The median duration of study was 47 days.

  3. Maximum Observed Concentration (Cmax) of Panitumumab

    Panitumumab serum concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 400 pg/mL. Concentrations below the LLOQ were set to zero.

    Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).

  4. Minimum Observed Concentration (Cmin) of Panitumumab

    Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).

  5. Area Under the Concentration-time Curve During the Dosing Interval (AUC0-tau) for Panitumumab

    The area under the serum concentration-time curve from time zero to the end of the dosing interval (AUCtau), estimated using the linear trapezoidal method.

    Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).

  6. Half-life (t1/2) for the Terminal Phase (First Dose) or Dosing Interval (Third Dose) of Panitumumab

    Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).

  7. Serum Clearance (CL) of Panitumumab

    Time frame: First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).

Secondary outcomes

  1. Number of Participants Who Developed Antibodies to Panitumumab

    Three validated assays were used to detect the presence of anti-panitumumab antibodies. Two screening immunoassays, an acid-dissociation enzyme-linked immunosorbent assay (ELISA) and a Biacore-based biosensor assay, were used to detect antibodies capable of binding to panitumumab. All samples confirmed to be positive by drug specificity in either screening immunoassay were further tested for neutralizing antibodies in a cell-based epidermal growth factor receptor (EGFR) phosphorylation bioassay. The number of participants who developed antibodies to panitumumab is the number of participants with a non-positive (including missing) antibody result at baseline and a positive antibody result at any post-baseline time point.

    Time frame: Before panitumumab administration on Day 1, Day 43, Day 169 and 30 days after last dose for all cohorts.

  2. Percentage of Participants With an Objective Response

    Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria. A participant was considered a responder if their best response was either a complete or partial response. Participants without a post-baseline assessment were considered non-responders. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response (CR): Disappearance of all target and non-target lesions, normalization of tumor markers and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions, no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions, persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD) or/and maintenance of tumor marker level above normal limits, and no new lesions.

    Time frame: Tumor response was assessed every 8 weeks through week 48 and every 3 months thereafter until disease progression or end of study. The data cut-off for the analysis was 17 June 2015; median duration of study was 47 days.

  3. Percentage of Participants With Disease Control

    Disease assessments were based on investigator review of scans using modified RECIST version 1.0 criteria. A participant was considered to have disease control if their best response is either a complete or partial response, or stable disease. Participants without a post-baseline assessment were considered to not have disease control. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. A best overall response of SD requires a visit response of SD or better, no earlier than 49 days after the date of enrollment. Stable disease (SD): Neither sufficient shrinkage of target lesions to qualify for a PR nor sufficient increase to qualify for PD and no progression of existing non-target lesions and no new lesions.

    Time frame: Tumor response was assessed every 8 weeks through week 48 and every 3 months thereafter until disease progression or end of study. The data cut-off for the analysis was 17 June 2015; median duration of study was 47 days.

07

Results

Posted May 18, 2016

Participant flow

This study was conducted at 7 centers in the United States. Participants were enrolled from 14 March 2008 to 4 March 2015.

Participant flow — Overall Study
MilestoneAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Started67468
Completed15443
Not completed52025
Withdrew: Withdrawal by subject01000
Withdrew: Death40011
Withdrew: Disease progression01013
Withdrew: Protocol-specified criteria10000
Withdrew: Other00001

Outcome measures

PrimaryNumber of Participants With Dose-limiting Toxicities (DLTs)

Any panitumumab related grade 3 or 4 hematologic or non-hematologic toxicity (graded according to the modified Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 criteria) was considered a DLT with the exception of alopecia and fatigue. Hypomagnesemia, nausea, diarrhea, vomiting, and skin or nail toxicities constituted a DLT only of the following occured: • Grade 3 or 4 hypomagnesemia that persisted for at least 5 days despite maximal magnesium replacement; • Grade 3 or 4 diarrhea, nausea, or vomiting that persisted for at least 5 days despite maximum supportive therapy; • Grade 4 skin or nail toxicity.

Time frame:
28 days from initial administration of panitumumab for the 2.5 and 6 mg/kg cohorts and 21 days from first administration for the 9 mg/kg cohort.
Reported as:
Number · participants
Number of Participants With Dose-limiting Toxicities (DLTs)
participantsAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Number of Participants With Dose-limiting Toxicities (DLTs)10013
SecondaryNumber of Participants Who Developed Antibodies to Panitumumab

Three validated assays were used to detect the presence of anti-panitumumab antibodies. Two screening immunoassays, an acid-dissociation enzyme-linked immunosorbent assay (ELISA) and a Biacore-based biosensor assay, were used to detect antibodies capable of binding to panitumumab. All samples confirmed to be positive by drug specificity in either screening immunoassay were further tested for neutralizing antibodies in a cell-based epidermal growth factor receptor (EGFR) phosphorylation bioassay. The number of participants who developed antibodies to panitumumab is the number of participants with a non-positive (including missing) antibody result at baseline and a positive antibody result at any post-baseline time point.

Time frame:
Before panitumumab administration on Day 1, Day 43, Day 169 and 30 days after last dose for all cohorts.
Reported as:
Number · participants
Number of Participants Who Developed Antibodies to Panitumumab
participantsAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Binding antibodies10020
Neutralizing antibodies00000
PrimaryNumber of Participants With Adverse Events (AEs)

A serious adverse event is defined as an AE that: • is fatal; • is life threatening; • requires in-patient hospitalization or prolongation of existing hospitalization; • results in persistent or significant disability/incapacity; • is a congenital anomaly/birth defect; • other significant medical hazard. The investigator assessed whether adverse events were related to panitumumab. The severity of adverse events was based on CTCAE version 3 (with the exception of skin- or nail-related toxicities which were graded using the CTCAE version 3.0 with modifications), according to the following: Grade 1 = Mild (aware of sign or symptom, but easily tolerated); Grade 2 = Moderate (discomfort enough to cause interference with usual activity); Grade 3 = Severe (incapacitating with inability to work or do usual activity); Grade 4 = Life-threatening or disabling; Grade 5 = Fatal.

Time frame:
From first dose date to end of study date. The median duration of study was 47 days.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Any adverse event67368
Serious adverse events53235
Treatment-related adverse event55356
Treatment-related serious adverse event10012
Withdrawals due to adverse event00000
Grade 157366
Grade 256347
Grade 345246
Grade 440012
Fatal40011
PrimaryMaximum Observed Concentration (Cmax) of Panitumumab

Panitumumab serum concentration was measured using an enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification (LLOQ) of the assay was 400 pg/mL. Concentrations below the LLOQ were set to zero.

Time frame:
First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Reported as:
Mean · μg/mL
Maximum Observed Concentration (Cmax) of Panitumumab
μg/mLAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
First Dose (n=6, 7, 3, 4, 7)52.8 ± 11.4161 ± 41.2205 ± 45.942.9 ± 8.51120 ± 29.4
Third Dose (n=3, 5, 1, 3, 2)76.6 ± 21.1187 ± 45.2327 ± NA60.8 ± 15.7126 ± NA
PrimaryMinimum Observed Concentration (Cmin) of Panitumumab
Time frame:
First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Reported as:
Mean · μg/mL
Minimum Observed Concentration (Cmin) of Panitumumab
μg/mLAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
First Dose (n=4, 7, 2, 4, 5)6.62 ± 6.8324.7 ± 18.635.3 ± NA4.87 ± 3.6419.7 ± 15.5
Third Dose (n=3, 5, 0, 3, 2)24.2 ± 22.948.1 ± 25.1NA ± NA17.3 ± 8.8326.1 ± NA
PrimaryArea Under the Concentration-time Curve During the Dosing Interval (AUC0-tau) for Panitumumab

The area under the serum concentration-time curve from time zero to the end of the dosing interval (AUCtau), estimated using the linear trapezoidal method.

Time frame:
First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Reported as:
Mean · day*μg/mL
Area Under the Concentration-time Curve During the Dosing Interval (AUC0-tau) for Panitumumab
day*μg/mLAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
First Dose (n=4, 7, 2, 4, 5)167 ± 86.11040 ± 3571580 ± NA127 ± 37.9708 ± 247
Third Dose (n=3, 5, 0, 3, 2)306 ± 1781330 ± 357NA ± NA255 ± 70.7754 ± NA
PrimaryHalf-life (t1/2) for the Terminal Phase (First Dose) or Dosing Interval (Third Dose) of Panitumumab
Time frame:
First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Reported as:
Mean · days
Half-life (t1/2) for the Terminal Phase (First Dose) or Dosing Interval (Third Dose) of Panitumumab
daysAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
First Dose (n=2, 5, 1, 3, 3)1.33 ± NA4.49 ± 1.094.27 ± NA2.11 ± 0.9134.23 ± 1.64
Third Dose (n=2, 2, 0, 1, 1)2.94 ± NA4.98 ± NANA ± NA3.07 ± NA4.91 ± NA
PrimarySerum Clearance (CL) of Panitumumab
Time frame:
First dose (Day 1) and third dose (Day 15/29/43 for the QW, Q2W and Q3W cohorts respectively). Samples were collected over the dosing interval for each treatment cohort (7, 14 or 21 days for QW, Q2W and Q3W cohorts respectively).
Reported as:
Mean · mL/day/kg
Serum Clearance (CL) of Panitumumab
mL/day/kgAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
First Dose (n=3, 5, 1, 4, 3)19.8 ± 8.576.38 ± 0.4667.15 ± NA18.7 ± 6.358.06 ± 1.40
Third Dose (n=3, 5, 0, 3, 2)9.92 ± 4.404.69 ± 1.00NA ± NA10.1 ± 2.448.05 ± NA
SecondaryPercentage of Participants With an Objective Response

Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 criteria. A participant was considered a responder if their best response was either a complete or partial response. Participants without a post-baseline assessment were considered non-responders. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response (CR): Disappearance of all target and non-target lesions, normalization of tumor markers and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions, no progression of non-target lesions and no new lesions, or, the disappearance of all target lesions, persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease (PD) or/and maintenance of tumor marker level above normal limits, and no new lesions.

Time frame:
Tumor response was assessed every 8 weeks through week 48 and every 3 months thereafter until disease progression or end of study. The data cut-off for the analysis was 17 June 2015; median duration of study was 47 days.
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response
percentage of participantsAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Percentage of Participants With an Objective Response0.00 (0.00 to 60.24)0.00 (0.00 to 70.76)0.00 (0.00 to 60.24)0.00 (0.00 to 84.19)0.00 (0.00 to 70.76)
SecondaryPercentage of Participants With Disease Control

Disease assessments were based on investigator review of scans using modified RECIST version 1.0 criteria. A participant was considered to have disease control if their best response is either a complete or partial response, or stable disease. Participants without a post-baseline assessment were considered to not have disease control. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. A best overall response of SD requires a visit response of SD or better, no earlier than 49 days after the date of enrollment. Stable disease (SD): Neither sufficient shrinkage of target lesions to qualify for a PR nor sufficient increase to qualify for PD and no progression of existing non-target lesions and no new lesions.

Time frame:
Tumor response was assessed every 8 weeks through week 48 and every 3 months thereafter until disease progression or end of study. The data cut-off for the analysis was 17 June 2015; median duration of study was 47 days.
Reported as:
Number · percentage of participants
Percentage of Participants With Disease Control
percentage of participantsAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Percentage of Participants With Disease Control0.00 (0.00 to 60.24)33.33 (0.84 to 90.57)0.00 (0.00 to 60.24)50.00 (1.26 to 98.74)66.67 (9.43 to 99.16)

Adverse events

Collected over From first dose date to end of study date. The median duration of study is 47 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Age 12-17: 2.5 mg/kg QW—5/6 (83.3%)5/6 (83.3%)
Age 12-17: 6 mg/kg Q2W—3/7 (42.9%)7/7 (100%)
Age 12-17: 9 mg/kg Q3W—2/4 (50%)3/4 (75%)
Age 1-11: 2.5 mg/kg QW—3/6 (50%)6/6 (100%)
Age 1-11: 6 mg/kg Q2W—5/8 (62.5%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Haemoglobin decreasedInvestigations2/60/70/40/60/8
TachycardiaCardiac disorders0/60/71/40/60/8
PyrexiaGeneral disorders0/60/71/40/60/8
HypoxiaRespiratory, thoracic and mediastinal disorders1/60/70/40/62/8
Pleural effusionRespiratory, thoracic and mediastinal disorders0/61/71/40/61/8
HypotensionVascular disorders0/60/71/40/60/8
Abdominal painGastrointestinal disorders1/60/70/40/60/8
AscitesGastrointestinal disorders1/60/70/40/60/8
PancreatitisGastrointestinal disorders1/60/70/40/60/8
VomitingGastrointestinal disorders0/60/70/41/61/8
Most frequent other events
Showing 10 of 163
Most frequent other events
EventAge 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2W
Dermatitis acneiformSkin and subcutaneous tissue disorders2/65/70/40/60/8
VomitingGastrointestinal disorders0/60/71/44/61/8
FatigueGeneral disorders1/64/72/40/62/8
Dry skinSkin and subcutaneous tissue disorders0/64/72/41/63/8
AnaemiaBlood and lymphatic system disorders0/60/72/40/60/8
TachycardiaCardiac disorders0/60/72/40/61/8
Abdominal painGastrointestinal disorders2/61/72/40/60/8
ConstipationGastrointestinal disorders3/63/71/41/60/8
Chest painGeneral disorders0/60/72/40/60/8
HypocalcaemiaMetabolism and nutrition disorders1/60/72/40/60/8

Baseline characteristics

Age, Continuous
Age, Continuous(years)Age 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2WTotal
Mean13.2 ± 0.815.6 ± 1.515.8 ± 1.97.8 ± 3.18.4 ± 2.811.8 ± 4.1
Sex: Female, Male
Sex: Female, Male(Participants)Age 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2WTotal
Female3133414
Male3613417
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Age 12-17: 2.5 mg/kg QWAge 12-17: 6 mg/kg Q2WAge 12-17: 9 mg/kg Q3WAge 1-11: 2.5 mg/kg QWAge 1-11: 6 mg/kg Q2WTotal
Asian020002
Black (or African American)110103
Hispanic or Latino001012
Other000101
White or Caucasian5434723
08

Study locations

11 sites
  • Research Site
    Los Angeles, California 90027, United States
  • Research Site
    San Francisco, California 94143, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Minneapolis, Minnesota 55455, United States
  • Research Site
    Kansas City, Missouri 64108, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    Cleveland, Ohio 44106, United States
  • Research Site
    Portland, Oregon 97239-3098, United States
  • Research Site
    Nashville, Tennessee 37232, United States
  • Research Site
    Houston, Texas 77030, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2008
First posted
Apr 15, 2008
Start
Mar 2008
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
May 18, 2016
Last update
May 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00658658
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Apr 15, 2008
Start date
Mar 2008
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
May 18, 2016
Last update
May 18, 2016

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion